Spots Global Cancer Trial Database for tazemetostat
Every month we try and update this database with for tazemetostat cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation | NCT06068881 | Follicular Lymp... Refractory Foll... | Tazverik (Tazem... | 18 Years - | Ipsen | |
| Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma | NCT05152459 | Recurrent Folli... Refractory Foll... | Tazemetostat Ublituximab Umbralisib | 18 Years - | City of Hope Medical Center | |
| Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma | NCT06242834 | B-Cell Non-Hodg... | Biospecimen Col... Computed Tomogr... Echocardiograph... Pembrolizumab Positron Emissi... Tazemetostat | 18 Years - | Northwestern University | |
| Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma | NCT04225429 | Epithelioid Sar... | Tazemetostat | 18 Years - | Ipsen | |
| Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma | NCT04624113 | Head and Neck S... | Tazemetostat Pembrolizumab | 18 Years - | Washington University School of Medicine | |
| Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC | NCT04846478 | Metastatic Pros... Metastatic Cast... | Talazoparib Tazemetostat | 18 Years - | Dana-Farber Cancer Institute | |
| A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma | NCT02601937 | Rhabdoid Tumors INI1-negative T... Synovial Sarcom... Malignant Rhabd... | Tazemetostat | 6 Months - 17 Years | Epizyme, Inc. | |
| A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. | NCT05205252 | Relapsed Hemato... Refractory Hema... | Tazemetostat Tafasitamab Lenalidomide Acalabrutinib Daratumumab (In... Mosunetuzumab Daratumumab (Su... Hyaluronidase-F... Pomalidomide Dexamethasone 2... | 18 Years - | Ipsen | |
| Combining Epigenetic And Immune Therapy to Beat Cancer. | NCT04705818 | Advanced Solid ... Advanced Colore... Advanced Soft-t... Advanced Pancre... Adult Solid Tum... | Durvalumab Tazemetostat | 18 Years - | Institut Bergonié | |
| Study of Tazemetostat in Lymphoid Malignancies | NCT05983965 | T-cell Lymphoma | Tazemetostat | 18 Years - | University of Alabama at Birmingham | |
| Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients | NCT03028103 | Diffuse Large B... Primary Mediast... Mantle Cell Lym... Advanced Solid ... Marginal Zone L... | Tazemetostat Fluconazole Omeprazole Repaglinide | 18 Years - | Ipsen | |
| EZH2 Inhibitor, Tazemetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer | NCT05467748 | Non Small Cell ... | Tazemetostat | 18 Years - | VA Office of Research and Development | |
| Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction | NCT03217253 | Ann Arbor Stage... Ann Arbor Stage... Metastatic Mali... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IIIC Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable So... | Laboratory Biom... Pharmacological... Tazemetostat | 18 Years - | National Cancer Institute (NCI) | |
| Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients | NCT03028103 | Diffuse Large B... Primary Mediast... Mantle Cell Lym... Advanced Solid ... Marginal Zone L... | Tazemetostat Fluconazole Omeprazole Repaglinide | 18 Years - | Ipsen | |
| A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma | NCT02220842 | Lymphoma | Atezolizumab Obinutuzumab Tazemetostat | 18 Years - | Hoffmann-La Roche | |
| A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas | NCT05934838 | Follicular Lymp... B-Cell Lymphoma Mantle Cell Lym... Diffuse Large B... | Tazemetostat Pi... | 18 Years - | Weill Medical College of Cornell University | |
| Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation | NCT03456726 | Relapsed or Ref... | Tazemetostat | 20 Years - | Eisai Inc. | |
| Study to Describe the Interaction Between Tazemetostat and Itraconazole and Between Tazemetostat and Rifampin in Participants With Advanced Cancer | NCT04537715 | All Malignancie... Advanced Malign... Hematologic Mal... Solid Tumor Follicular Lymp... Non-Hodgkin Lym... Diffuse Large B... Epithelioid Sar... Synovial Sarcom... Renal Medullary... Mesothelioma Rhabdoid Tumor | Tazemetostat Itraconazole Tazemetostat Rifampin | 18 Years - | Ipsen | |
| Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment | NCT05627245 | Recurrent B-Cel... Recurrent Diffu... Recurrent Non-H... Recurrent Prima... Recurrent T-Cel... Recurrent Trans... Refractory B-Ce... Refractory Diff... Refractory Non-... Refractory Prim... Refractory T-Ce... Refractory Tran... | Belinostat Biopsy Biospecimen Col... Computed Tomogr... Pharmacokinetic... Positron Emissi... Tazemetostat | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma | NCT05551936 | Follicular Lymp... | Bendamustine Rituximab Tazemetostat | 18 Years - | Big Ten Cancer Research Consortium | |
| A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation | NCT06068881 | Follicular Lymp... Refractory Foll... | Tazverik (Tazem... | 18 Years - | Ipsen | |
| Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL | NCT01897571 | B-cell Lymphoma... Advanced Solid ... Diffuse Large B... Follicular Lymp... Transformed Fol... Primary Mediast... | Tazemetostat Prednisolone Tazemetostat | 16 Years - | Ipsen | |
| Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer | NCT03348631 | Recurrent Endom... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Uteri... | Computed Tomogr... Magnetic Resona... Tazemetostat | 18 Years - | National Cancer Institute (NCI) | |
| Tazemetostat in Malignant Peripheral Nerve Sheath Tumors | NCT04917042 | Peripheral Nerv... | Tazemetostat | 12 Years - 99 Years | University of Florida | |
| A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan | NCT05228158 | Lymphoma, Folli... | Tazemetostat | - | Eisai Inc. | |
| A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | NCT03009344 | Relapsed or Ref... | Tazemetostat | 20 Years - | Eisai Inc. | |
| Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma | NCT06242834 | B-Cell Non-Hodg... | Biospecimen Col... Computed Tomogr... Echocardiograph... Pembrolizumab Positron Emissi... Tazemetostat | 18 Years - | Northwestern University | |
| Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma | NCT04624113 | Head and Neck S... | Tazemetostat Pembrolizumab | 18 Years - | Washington University School of Medicine | |
| Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma | NCT04225429 | Epithelioid Sar... | Tazemetostat | 18 Years - | Ipsen | |
| A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation | NCT06068881 | Follicular Lymp... Refractory Foll... | Tazverik (Tazem... | 18 Years - | Ipsen | |
| Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL | NCT01897571 | B-cell Lymphoma... Advanced Solid ... Diffuse Large B... Follicular Lymp... Transformed Fol... Primary Mediast... | Tazemetostat Prednisolone Tazemetostat | 16 Years - | Ipsen | |
| A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation | NCT06068881 | Follicular Lymp... Refractory Foll... | Tazverik (Tazem... | 18 Years - | Ipsen | |
| A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan | NCT05228158 | Lymphoma, Folli... | Tazemetostat | - | Eisai Inc. | |
| A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas | NCT05934838 | Follicular Lymp... B-Cell Lymphoma Mantle Cell Lym... Diffuse Large B... | Tazemetostat Pi... | 18 Years - | Weill Medical College of Cornell University | |
| Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal Carcinoma | NCT05151588 | Sinonasal Carci... | Docetaxel Cis Platinum 5-FU Tazemetostat Surgery Chemoradiation | 18 Years - | The University of Hong Kong | |
| Palbociclib or Tazemetostat in Combination With CPX-351 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | NCT05627232 | Recurrent Acute... Refractory Acut... | Tazemetostat Liposome-encaps... Bone Marrow Asp... Biospecimen Col... Palbociclib | 18 Years - | Thomas Jefferson University | |
| A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma | NCT05551936 | Follicular Lymp... | Bendamustine Rituximab Tazemetostat | 18 Years - | Big Ten Cancer Research Consortium | |
| A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma | NCT05372354 | Multiple Myelom... | CC-92480 Tazemetostat BMS-986158 Trametinib Dexamethasone | 18 Years - | Bristol-Myers Squibb | |
| Tazemetostat in Malignant Peripheral Nerve Sheath Tumors | NCT04917042 | Peripheral Nerv... | Tazemetostat | 12 Years - 99 Years | University of Florida | |
| A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma | NCT02220842 | Lymphoma | Atezolizumab Obinutuzumab Tazemetostat | 18 Years - | Hoffmann-La Roche | |
| A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas | NCT05934838 | Follicular Lymp... B-Cell Lymphoma Mantle Cell Lym... Diffuse Large B... | Tazemetostat Pi... | 18 Years - | Weill Medical College of Cornell University | |
| A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | NCT03009344 | Relapsed or Ref... | Tazemetostat | 20 Years - | Eisai Inc. | |
| Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation | NCT03456726 | Relapsed or Ref... | Tazemetostat | 20 Years - | Eisai Inc. | |
| Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors | NCT05407441 | Atypical Terato... INI1 (SMARCB1)-... SMARCA4-deficie... Malignant Rhabd... Rhabdoid Tumor ... Epithelioid Sar... Chordoma | Tazemetostat Nivolumab Ipilimumab | 6 Months - 21 Years | Dana-Farber Cancer Institute | |
| SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma | NCT04762160 | Follicular Lymp... | Tazemetostat Rituximab | 18 Years - | Ipsen | |
| Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma | NCT05994235 | Follicular Lymp... | Mosunetuzumab Tazemetostat Pi... | 18 Years - | Weill Medical College of Cornell University | |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | NCT03155620 | Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Histiocytic Sar... Juvenile Xantho... Langerhans Cell... Malignant Gliom... Recurrent Child... Recurrent Epend... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Prima... Recurrent Rhabd... Recurrent Soft ... Refractory Ewin... Refractory Glio... Refractory Hepa... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Prim... Refractory Rhab... Refractory Rhab... Rhabdoid Tumor Stage III Osteo... Stage III Soft ... Stage IV Osteos... Stage IV Soft T... Stage IVA Osteo... Stage IVB Osteo... Wilms Tumor | Biopsy Biospecimen Col... Bone Marrow Asp... Bone Scan Computed Tomogr... Ensartinib Erdafitinib Laboratory Biom... Larotrectinib S... Magnetic Resona... Mutation Carrie... Olaparib Palbociclib Pharmacological... Positron Emissi... Radionuclide Im... Samotolisib Selpercatinib Selumetinib Sul... Tazemetostat Tipifarnib Ulixertinib Vemurafenib X-Ray Imaging | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma | NCT05618366 | Lymphoma, Non-H... Diffuse Large B... Follicular Lymp... | Venetoclax Tazemetostat | 18 Years - | Weill Medical College of Cornell University | |
| A Study to Assess the Long-term Safety of Tazemetostat | NCT02875548 | Diffuse Large B... Follicular Lymp... Synovial Sarcom... Epitheliod Sarc... Mesothelioma Advanced Solid ... Renal Medullary... Non-Hodgkin Lym... | Tazemetostat | 18 Years - | Ipsen |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
